Article
Endocrinology & Metabolism
Ki Young Huh, Jun Gi Hwang, Wonjung Shin, Seungjae Baek, JaeDuk Choi, Nora Lee, Young Min Cho, Howard Lee
Summary: HM15136, a novel long-acting glucagon analogue, was shown to be safe and well tolerated in doses ranging from 10-120 μg/kg in a randomized, double-blind, placebo-controlled study. It increased blood glucose levels and suppressed the secretion of endogenous glucagon.
DIABETES OBESITY & METABOLISM
(2022)
Article
Pharmacology & Pharmacy
Xue Zhao, Hongzhong Liu, Wei Tian, Ligang Fang, Mengyang Yu, Xiaofei Wu, Aijing Liu, Ruijie Wan, Li Li, Jinghui Luo, Yuqiong Li, Bo Liu, Yu He, Xiaowen Chen, Yuan Li, Donghong Xu, Hongyun Wang, Xiaohong Han
Summary: This study aimed to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of aficamten in healthy Chinese adults. The results showed that aficamten was safe and well-tolerated in the Chinese population, with pharmacokinetics comparable to Western participants. These findings support future clinical studies of aficamten in Chinese patients.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Yijing Liao, Anran Ma, Zhihong Wang, Yue Zhou, Lin Liu, Na Zhang, Li Zhang, Gerald J. Prud'homme, Qinghua Wang
Summary: This study demonstrated that supaglutide has linear pharmacokinetic characteristics and can produce prolonged hypoglycemic effects, suggesting its potential as a weekly dosing therapeutic agent for the treatment of type 2 diabetes and metabolic diseases.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Cuiyun Li, Wei Xiang, Min Wu, Hong Zhang, Jianqiu Cheng, Tao Yang, Jiajia Mai, Xiumei Chi, Xiuzhu Gao, Yanhua Ding, Junqi Niu
Summary: The study demonstrates that rHA is safe and well-tolerated in healthy subjects, showing similar safety and pharmacokinetic/pharmacodynamic profiles with HSA. These results support further evaluation of rHA treatment in cirrhotic patients with ascites.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Manon L. M. Prins, Johan L. van der Plas, Maurits F. J. M. Vissers, Cecile L. Berends, Gaby Tresch, Marianne Soergel, Elena Fernandez, Nikita van den Berge, Daniel Duijsings, Christof Zitt, Vaia Stavropoulou, Maya Zimmermann, Roxana F. Drake, Jacobus Burggraaf, Geert H. Groeneveld, Ingrid M. C. Kamerling
Summary: This study evaluated the impact of ensovibep on viral clearance, pharmacokinetics, tolerability, and symptom evolution in outpatients with mild-to-moderate COVID-19. The results showed that single-dose intravenous administration of ensovibep was safe and well tolerated, with favorable pharmacokinetics and therapeutic effects in patients. Further research is warranted based on the pharmacodynamic results.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Endocrinology & Metabolism
Edward Pratt, Xiaosu Ma, Rong Liu, Deborah Robins, Axel Haupt, Tamer Coskun, Kyle W. Sloop, Charles Benson
Summary: This study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of orforglipron, an oral GLP-1RA. The drug had a long half-life and showed similar efficacy and safety as injectable GLP-1RAs, suggesting potential for further clinical development.
DIABETES OBESITY & METABOLISM
(2023)
Article
Pharmacology & Pharmacy
Kalpna Jakhar, Swetha Vaishnavi, Prabhsimran Kaur, Paramdeep Singh, Anjana Munshi
Summary: This review discusses the role and influencing factors of GLP-1RA drugs in the treatment of type 2 diabetes, as well as information on their pharmacokinetics and pharmacodynamics.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Dominic Beale, Jeremy Dennison, Malcolm Boyce, Francesca Mazzo, Naoki Honda, Paul Smith, Mark Bruce
Summary: The study demonstrated that ONO-7684 was well-tolerated in healthy subjects at both single and multiple doses, with low incidence of adverse events. Pharmacokinetic data showed dose proportionality for ONO-7684. Pharmacodynamic results revealed a strong inhibition of FXI coagulation activity and an increase in aPTT at 250 mg ONO-7684 daily. These findings support the potential of ONO-7684 as an oral FXIa inhibitor for anticoagulation indications.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Endocrinology & Metabolism
Wonjung Shin, Marcus Hompesch, JinHee Byeon, Seohyun Kang, Jaehyuk Choi, Seungjae Baek
Summary: This study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of a novel long-acting glucagon analogue HM15136 in overweight/obese patients with co-morbidities, with and without type 2 diabetes (T2D). The results showed that HM15136 had good safety and tolerability in patients with dyslipidaemia and/or hypertension, but its use in patients with T2D may cause hyperglycaemia.
DIABETES OBESITY & METABOLISM
(2023)
Article
Medicine, General & Internal
Cuiyun Li, Min Wu, Hong Zhang, Xiaoxue Zhu, Li Fu, Shuo Wang, Mingming Lu, Dafang Zhong, Yanhua Ding
Summary: This study evaluated the safety and pharmacokinetic profiles of forsythin in healthy Chinese subjects. The results showed that forsythin is well-absorbed and extensively metabolized after single or multiple doses. The findings support further evaluation of its efficacy in individuals with the common cold or influenza.
ANNALS OF MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Suping Niu, Min Chen, Diqin Yan, Xiangxing Liu, Shuren Guo, Lun Ou, Huaying Fan, Jie Lv, Qian Wang, Wenliang Dong, Lin Xia, Simin Wang, Gang Liu, Qun Gu, Danjie Guo, Hongxia Liu, Huiying Rao, Qingshan Zheng, Xiaoyan Nie, Haifeng Song, Yi Fang
Summary: This study aimed to explore the safety and efficacy of LY06006 when administered subcutaneously in healthy Chinese adults. The results showed that single-dose subcutaneous administration of LY06006 was safe and well-tolerated in this population, and exhibited linear pharmacokinetic characteristics.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Medicinal
Mingzhi Xu, Gang Chen, Yanan Dong, Jing Yang, Yongxue Liu, Haijing Song, Haifeng Song, Yi Wang
Summary: Bovine milk contains mEVs, which can serve as an orally bioavailable drug delivery vehicle. Sublingual administration of mEVs was found to result in systemic uptake, whereas gavage administration showed lower absorption levels. Furthermore, mEVs loaded with an antidiabetic drug demonstrated efficacy in reducing blood glucose levels when given sublingually but not via gavage.
Article
Chemistry, Medicinal
Inseung Jeon, Jaeseong Oh, Yu-Kyung Kwon, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang, Kyung-Sang Yu, SeungHwan Lee
Summary: The study compared the pharmacokinetic (PK), pharmacodynamic (PD), and tolerability profiles of CKD-11101 with those of the reference drug in healthy subjects. Results showed that CKD-11101 was well tolerated and exhibited comparable PK and PD characteristics with the reference drug after a single intravenous (IV) or subcutaneous (SC) dose.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Pharmacology & Pharmacy
Ling Yang, Pei Shu, Nan Wu, Mengyue Hu, Zhu Luo
Summary: The study aimed to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198 in healthy subjects. The results showed that FTP-198 had good pharmacokinetic properties in healthy subjects, effectively inhibited the content of plasma lysophosphatidic acid (LPA) 18:2, and exhibited favorable safety and tolerability. These results support further subsequent clinical development of FTP-198 in IPF patients.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2023)
Article
Surgery
David J. Taber, Felicia Bartlett, Neha Patel, Taylor Sprague, Shikha Patel, Jessica Newman, Erika Andrade, Nikhil Rao, Maria Aurora Posadas Salas, Michael Casey, Derek Dubay, Vinayak Rohan
Summary: The effect of converting to once daily, extended-release LCP-Tacrolimus for kidney transplant recipients with high tacrolimus variability has been investigated in a retrospective cohort study. The results demonstrate that conversion to LCP-Tac significantly reduces variability and improves therapeutic range, especially in patients with nonadherence or medication errors.
CLINICAL TRANSPLANTATION
(2023)
